InsidersTradesSigma
Total declarations
Companies
▲ Purchases (26 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
26
Disclosed sells
1
T+90 hit rate
50%
T+90 mean return
+6.9%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by ADAR1 Capital Management, LLC. Director active across 6 companies, notably Rallybio Corp. In total, 30 disclosures have been published. Split: 26 buys · 1 sell. Total volume traded: €71.7m. History available since 9 August 2024. The latest transaction was filed on 20 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to ADAR1 Capital Management, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations30 total
202,124 shares@ US$1.7788Common StockSEC:0001940272-26-000017:0
Canonical exit: 18 Nov 2026 (T+90)
716,369 shares@ US$1.7676Common StockSEC:0001940272-26-000017:1
Canonical exit: 19 Nov 2026 (T+90)
107,374 shares@ US$1.7542Common StockSEC:0001940272-26-000017:2
Canonical exit: 22 Nov 2026 (T+90)
3,300 shares@ US$4.97580.054% mcap1.0% of flowCommon StockSEC:0001940272-26-000013:6
Canonical exit: 29 Oct 2026 (T+90)
50,000 shares@ US$4.97230.82% mcap14.5% of flowCommon StockSEC:0001940272-26-000013:0
Canonical exit: 28 Oct 2026 (T+90)
25,000 shares@ US$4.81350.40% mcap7.0% of flowCommon StockSEC:0001940272-26-000013:3
Canonical exit: 28 Oct 2026 (T+90)
77,850 shares@ US$4.95561.27% mcap22.5% of flowCommon StockSEC:0001940272-26-000013:5
Canonical exit: 28 Oct 2026 (T+90)
20,000 shares@ US$5.000.33% mcap5.8% of flowCommon StockSEC:0001940272-26-000013:2
Canonical exit: 28 Oct 2026 (T+90)
20,000 shares@ US$5.000.33% mcap5.8% of flowCommon StockSEC:0001940272-26-000013:1
Canonical exit: 28 Oct 2026 (T+90)
100,000 shares@ US$4.901.61% mcap28.6% of flowCommon StockSEC:0001940272-26-000013:4
Canonical exit: 28 Oct 2026 (T+90)
8,003 shares@ US$4.800.13% mcap2.2% of flowCommon StockSEC:0001940272-26-000013:8
Canonical exit: 29 Oct 2026 (T+90)
25,000 shares@ US$4.98160.41% mcap7.2% of flowCommon StockSEC:0001940272-26-000013:7
Canonical exit: 29 Oct 2026 (T+90)
6,400 shares@ US$4.949636.2% of flowCommon StockSEC:0001940272-26-000012:1
Canonical exit: 26 Oct 2026 (T+90)
1,810 shares@ US$5.0010.3% of flowCommon StockSEC:0001940272-26-000012:2
Canonical exit: 27 Oct 2026 (T+90)
7,798 shares@ US$4.999444.4% of flowCommon StockSEC:0001940272-26-000012:0
Canonical exit: 25 Oct 2026 (T+90)
1,600 shares@ US$5.009.1% of flowCommon StockSEC:0001940272-26-000012:3
Canonical exit: 27 Oct 2026 (T+90)
1,000 shares@ US$1.5550.019% mcap0.2% of flowCommon SharesSEC:0001940272-26-000010:0
Canonical exit: 13 Oct 2026 (T+90)
68,551 shares@ US$1.59981.45% mcap15.2% of flowCommon SharesSEC:0001940272-26-000008:0
Canonical exit: 17 Aug 2026 (T+90)
200,000 shares@ US$1.56044.13% mcap43.3% of flowCommon SharesSEC:0001940272-26-000008:1
Canonical exit: 17 Aug 2026 (T+90)
200,000 shares@ US$1.4993.97% mcap41.5% of flowCommon SharesSEC:0001940272-26-000008:2
Canonical exit: 17 Aug 2026 (T+90)
75,178 shares@ US$14.001.16% mcap90.0% of flowCommon StockSEC:0001104659-26-062883:1
Canonical exit: 11 Aug 2026 (T+90)
100 shares@ US$13.800.0015% mcap0.1% of flowCommon StockSEC:0001104659-26-062883:2
Canonical exit: 13 Aug 2026 (T+90)
200 shares@ US$13.950.0031% mcap0.2% of flowCommon StockSEC:0001104659-26-062883:3
Canonical exit: 13 Aug 2026 (T+90)
4,081 shares@ US$13.79930.062% mcap50.0% of flowCommon StockSEC:0001104659-26-062883:0
Canonical exit: 11 Aug 2026 (T+90)
4,391,237 shares@ US$17.7599.6% of flowCommon StockSEC:0000902664-25-004411:0
25 of 30 declarations
About ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC is a declarant with 18 filings in total. Across the 18 sampled filings, buys total EUR 1850116 and sells total EUR 66926228, over the period from 2024-08-12 to 2026-07-29. The companies mentioned in these filings include Keros Therapeutics, Inc., NextCure, Inc., InMed Pharmaceuticals Inc., Rallybio Corp and Pieris Pharmaceuticals, INC., with 10% Owner roles for NextCure, Inc., InMed Pharmaceuticals Inc. and Rallybio Corp.
